Patent intelligence · US
US 11021542
Humanized BCMA antibody and BCMA-CAR-T cells
Humanized BCMA antibody and BCMA-CAR-T cells
Patent details — US 11021542
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 1, 2021
- Expiration
- May 27, 2041
- Applicant
- Caribou Biosciences, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K2035/124, A61K2039/505, A61K2039/54
Quick answer
US 11021542 (Humanized BCMA antibody and BCMA-CAR-T cells) is held by Caribou Biosciences, Inc.. Status: granted. Granted Jun 1, 2021. Expires May 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Caribou Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2035/124, A61K2039/505, A61K2039/54, A61K2039/804, A61K2239/31
More from Caribou Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11939604
Modified cascade ribonucleoproteins and uses thereof
granted -
US 11932703
Anti-ROR1 antibody and ROR1-targeting engineered cells
granted -
US 11472884
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 11312953
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 11299549
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 11142583
BCMA-CAR-natural killer (NK) cells and methods related thereto
granted -
US 10954498
Modified cascade ribonucleoproteins and uses thereof
granted
Frequently asked questions
What is US patent 11021542?
US 11021542 (Humanized BCMA antibody and BCMA-CAR-T cells) is held by Caribou Biosciences, Inc.. Status: granted. Granted Jun 1, 2021. Expires May 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11021542?
Caribou Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 19 pharmaceutical patents for this assignee.
When does US 11021542 expire?
Our index shows an expiration date of May 27, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.